Actuate Therapeutics (ACTU) vs Biofrontera (BFRI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biofrontera (BFRI) has outperformed Actuate Therapeutics (ACTU) over the past year, losing 6.7% versus a loss of 92.5%. Actuate Therapeutics is the larger company by market cap ($14.7 million vs $14.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACTU | BFRI |
|---|---|---|
| Share price | $0.6102 | $0.97 |
| Market cap | $14.65M | $14.41M |
| 1-day change | -10.13% | +5.57% |
| YTD return | -90.03% | +70.18% |
| 1-year return | -92.46% | -6.73% |
| Forward P/E | — | 2.26 |
| EPS (TTM) | $-0.87 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.49 | $1.66 |
| 52-week low | $0.604 | $0.555 |
| Distance from 52-week high | -92.81% | -41.57% |
| Analyst consensus | none | none |
| Avg. price target upside | +1814.13% | +518.56% |
| Average volume | 386.51K | 547.45K |
| Shares outstanding | 24.01M | 14.85M |
| Employees | 12 | 84 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BFRI has outperformed ACTU by 85.7 percentage points over the past year.
About Actuate Therapeutics
ACTU stock →Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
ACTU vs BFRI FAQ
Which is bigger, Actuate Therapeutics or Biofrontera?
Actuate Therapeutics (ACTU) is larger, with a market capitalization of $14.65M compared with $14.41M for Biofrontera (BFRI).
Which stock has performed better over the past year, ACTU or BFRI?
BFRI returned -6.73% over the past 12 months, compared with -92.46% for ACTU (price return, excluding dividends). Past performance does not predict future results.
Are Actuate Therapeutics and Biofrontera in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.